Back to top

Analyst Blog

GlaxoSmithKline (GSK - Analyst Report) recently announced the submission of a marketing application to the European Medicines Agency (EMA) for its diabetes candidate Eperzan (albiglutide). The company is looking to get the candidate approved for treating adults suffering from type II diabetes (once weekly).

A few weeks back, in Jan 2013, Glaxo had submitted a Biologics License Application (BLA) for Eperzan to the US Food and Drug Administration (FDA) seeking approval for the above mentioned indication.

The marketing application includes data from a phase III study (Harmony 8). We note that in Jul 2012, Glaxo had reported encouraging results from the Harmony 8 study, which evaluated Eperzan versus Merck’s (MRK - Analyst Report) Januvia (sitagliptin).

Approximately 507 type II diabetes patients with renal impairment were enrolled in the study. The drugs were compared on the basis of reduction in HbA1c, an indicator of glucose level in the blood.

Eperzan showed a statistically significant reduction in HbA1c from the baseline. Results showed that reduction in HbA1c in the Eperzan and Januvia arms were 8.08% and 8.22%, respectively. Additionally, the rate of weight loss was higher in the Eperzan arm.

Glaxo boasts a strong late-stage pipeline. The company is already seeking approval for several candidates including Relvar/Breo (chronic obstructive pulmonary disease/COPD and asthma), Anoro (COPD), dolutegravir (HIV), dabrafenib (oncology) and trametinib (oncology).

We are positive on the advancement of Glaxo’s pipeline programs. We believe the candidates hold immense commercial potential.

Glaxo carries a Zacks Rank #4 (Sell). Large-cap pharma companies that currently look better-positioned include Eli Lilly and Company (LLY - Analyst Report) and Novo Nordisk (NVO - Analyst Report). Both are Zacks Rank #2 (Buy) stocks.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%